SEC Form 4 · accession 0001144204-17-038499
Moleculin Biotech, Inc. · MBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D Cannon
Director
Period of report
Jul 24, 2017
Accepted (ET)
Jul 26, 2017 · 9:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001659617
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase common stockF2,F1 | $1.87 | Jul 24, 2017 | A | 15,000 | A | — | Jul 24, 2027 | Common Stock | 15,000 | 35,000 | D |
Explanation of responses
- F1The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.
- F2The options were issued in connection with the reporting person's Board of Director service to the Company.